Clinical Trial

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib (PARP inhibitor)and bevacizumab in platinum-sensitive relapsed ovarian cancer.
Trial Details
NCT Number NCT06446206
Lead Sponsor The First Hospital of Jilin University
Conditions Platinum-sensitive Relapsed Ovarian Cancer
Enrollment 22 participants
Start Date 2024-06
Primary Completion 2026-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2024-06-06